Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVX-410 and Durvalumab in Stage II/III TNBC
NCT02826434Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2016
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of pvx-410 in triple-negative breast cancer (TNBC), sponsored by Massachusetts General Hospital. Primary endpoint: Dose Limiting Toxicity Rate at 4 weeks. Started Aug 2016; status: active, not recruiting.
02
Drugs
pvx-410
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02826434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02826434.